Synergy Pharmaceuticals
- Company typePrivate
- Founded1992
- HeadquartersNew York, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Synergy Pharmaceuticals does
Synergy Pharmaceuticals was a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions. Founded in 1992 and headquartered in New York, the company was publicly traded on NASDAQ under the ticker symbol SGYP. It operated with a headcount in the 251-500 range and maintained a leadership team that included Kunwar Shailubhai as Chief Scientific Officer. The company's core focus was on developing therapeutics for gastrointestinal disorders, and it is referenced as a participant in the broader medical affairs outsourcing market, which was projected to grow at a 12.5% CAGR through 2032.
The company financed its operations through multiple capital raises, including a $300 million round led by CRG in September 2017 and an $89.8 million round in May 2016, alongside earlier financings from 2009 through 2014 involving investors such as Aisling Capital. Despite raising over $400 million cumulatively, the company reported deeply negative operating results across every reported year from 2013 through 2017, with operating losses compounding annually and culminating in massive net losses by 2017. The company did not achieve sustained profitability or meaningful revenue scale during its operating period.
The company appears to no longer be operating as an active enterprise. Its website, synergypharma.com, is currently a parked domain hosted by GoDaddy, with no active web presence, product portfolio, or investor relations content accessible. No current management, contact details, or operating geographies are available, and the firmographics data carries no recent operational signals. This strongly suggests the company has been dissolved, acquired without a successor entity, or otherwise ceased independent operations.
Synergy Pharmaceuticals firmographics
Firmographics- Name
- Synergy Pharmaceuticals
- Website
- https://synergypharma.com
- Company type
- Private
- Founded year
- 1992
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Synergy Pharmaceuticals industry classification
Industry- Product category
- Gastrointestinal Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where Synergy Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Synergy Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Synergy Pharmaceuticals product offering
Product offeringCore offering
Synergy Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions. Its core offering centers on proprietary drug development targeting chronic idiopathic constipation, irritable bowel syndrome with constipation (IBS-C), and related functional GI disorders. The company participates in the medical affairs outsourcing market as a key player, leveraging its specialized GI therapeutics pipeline and scientific capabilities.
Product overview
No specific product or service information is available in the provided sources. The company's website (synergypharma.com) is currently parked and inactive, indicating no active product portfolio information is accessible. The news sources reference market trends in pharmaceutical sectors (medical affairs outsourcing and oral protein/peptides markets) but do not provide details about Synergy Pharmaceuticals' specific product offerings.
Differentiator
Problem solved
Functional benefit
Products and services
- Novel gastrointestinal therapies (GI conditions pipeline) Novel therapies for the treatment of gastrointestinal conditions including chronic idiopathic constipation and IBS-C, developed as prescription therapeutics for healthcare providers and patients with functional GI disorders.
- Medical affairs outsourcing services Medical affairs outsourcing solutions for the pharmaceutical industry, leveraging the company's specialized gastrointestinal therapeutics expertise to serve pharmaceutical sponsor clients.
Companies that use Synergy Pharmaceuticals
Customer profileIdeal customer profiles1 record
Synergy Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Synergy Pharmaceuticals partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights2 records
Synergy Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Ardelyx: Specialty biopharma commercializing GI products (e.g., IBSRELA, XPHMAH/XPHOZAH for hyperphosphatemia in CKD). Comparable as a GI-focused specialty pharma with similar commercialization profile.
- RedHill Biopharma: Specialty pharma with a GI-dominated commercial portfolio (e.g., Talicia, Aemcolo, Movantik). Closely comparable specialty-GI commercial peer.
- Ironwood Pharmaceuticals (Cyclerion): Specialty GI biopharmaceutical company with a comparable gastroenterology focus (e.g., linaclotide franchise). Direct therapeutic-area and commercial-model peer for Synergy's GI pipeline.
- Bausch Health (Salix Pharmaceuticals): GI specialty pharma franchise (Salix) with products overlapping Synergy's gastroenterology focus. Direct therapeutic-area peer in marketing branded Rx GI products to gastroenterologists.
Broad incumbents
- Takeda Pharmaceutical: Global pharma with significant gastroenterology presence (e.g., Entyvio for IBD). Broad incumbent competing in the same GI therapeutic categories.
- AbbVie (Allergan): Large incumbent pharma with an established GI franchise (e.g., Linzess, via collaboration). Comparable as a broader gastroenterology competitor and potential acquirer/partner.
- Pfizer (GI Franchise): Mega-cap pharma with historical GI assets (e.g., gastroenterology partner of Ironwood). Relevant broad incumbent in the GI specialty space.
Emerging players
- Sebela Pharmaceuticals: Private specialty pharma focused on gastroenterology and women's health. Similar therapeutic focus with a smaller commercial footprint, comparable as a GI specialty peer.
- Phathom Pharmaceuticals: Specialty biopharma commercializing GI products (e.g., Voquezna for H. pylori and erosive GERD). Comparable small-cap GI specialty commercial peer.
- Intercept Pharmaceuticals: Biopharma focused on liver and GI diseases, including Ocaliva for primary biliary cholangitis. Comparable as a specialty biopharma in adjacent hepatology/GI therapeutic areas.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Synergy Pharmaceuticals social profiles
Digital presenceSynergy Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Synergy Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles1 record
Synergy Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Synergy Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Synergy Pharmaceuticals
What does Synergy Pharmaceuticals do?
Synergy Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions. Its core offering centers on proprietary drug development targeting chronic idiopathic constipation, irritable bowel syndrome with constipation (IBS-C), and related functional GI disorders. The company participates in the medical affairs outsourcing market as a key player, leveraging its specialized GI therapeutics pipeline and scientific capabilities.
When was Synergy Pharmaceuticals founded?
Synergy Pharmaceuticals was founded in 1992. It employs 251 to 500 people.
Where is Synergy Pharmaceuticals based?
Synergy Pharmaceuticals is headquartered in New York, United States, in the North America region.
Who are Synergy Pharmaceuticals's main competitors?
Direct peers on record are Ardelyx, RedHill Biopharma, Ironwood Pharmaceuticals (Cyclerion) and Bausch Health (Salix Pharmaceuticals). Broad incumbents are Takeda Pharmaceutical, AbbVie (Allergan) and Pfizer (GI Franchise). Emerging players are Sebela Pharmaceuticals, Phathom Pharmaceuticals and Intercept Pharmaceuticals.
Does Synergy Pharmaceuticals have an API?
No public API is recorded for Synergy Pharmaceuticals.
What industry is Synergy Pharmaceuticals in?
Synergy Pharmaceuticals's product category is Gastrointestinal Therapeutics. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.